Patient and physician adherence in hypertension management

Journal of Clinical Hypertension

Volumn 15, Issue 7, 2013, Pages 447-452

  Turner, J Rick ^a  

^a IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT;

BEHAVIOR CHANGE; BEHAVIORAL MEDICINE; CLINICAL PRACTICE; DOCTOR PATIENT RELATION; HEALTH CARE PERSONNEL; HEALTH EDUCATOR; HUMAN; HYPERTENSION; LIFESTYLE; MEDICAL SPECIALIST; NOTE; NURSE; PATIENT COMPLIANCE; PHARMACIST; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; PROTOCOL COMPLIANCE; PSYCHOLOGIST; TREATMENT REFUSAL;

ANTIHYPERTENSIVE AGENTS; BEHAVIORAL MEDICINE; DISEASE MANAGEMENT; HUMANS; HYPERTENSION; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIAN-PATIENT RELATIONS; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84879795652     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12105     Document Type: Note

References (70)

1. Horton R. GBD 2010: understanding disease, injury, and risk. Lancet. 2013;380:2053-2054.
2. Das P, Samarasekera U. The story of GBD 2010: a "super-human" effort. Lancet. 2013;380:2067-2070.
3. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380:2224-2260.
4. Dolan E, O'Brien E. Hypertension - the major cause of death and morbidity worldwide; where are our policy makers? Irish Medical Times. January 25th, 2013, page 33.
5. Nieuwlaat R, Schwalm JD, Khatib R, Yusuf S. Why are we failing to implement effective therapies in cardiovascular disease? Eur Heart J. 2013. Feb 1. [Epub ahead of print].
6. Dunbar-Jacob J, Houze MP, Kramer C, et al. Adherence to medical advice: process and measurement. In: Steptoe A, ed. Handbook of Behavioral Medicine: Methods and applications. New York: Springer, 2010, 83-95.
7. Gellman MD, Turner JR eds. Encyclopedia of Behavioral Medicine. New York: Springer, 2013.
8. Howren MB. Adherence. In: Gellman MD, Turner JR eds. Encyclopedia of Behavioral Medicine. New York: Springer, 2013, 33-39.
9. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
10. Chisholm-Burns MA, Spivey CA. The 'cost' of medication nonadherence: consequences we cannot afford to accept. J Am Pharm Assoc (2003). 2012;6:823-826.
11. Parati G, Omboni S, Compare A, et al. Blood pressure control and treatment adherence in hypertensive patients with metabolic syndrome: protocol of a randomized controlled study based on home blood pressure telemonitoring vs. conventional management and assessment of psychological determinants of adherence (TELEBPMET Study). Trials. 2013;14:22. [Epub ahead of print].
12. The Script Your Future Initiative. http://scriptyourfuture.org/. Accessed January 28, 2013.
13. Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev. 2010;3:CD004371.
14. Korsch BM, Gozzi EK, Francis V. Gaps in doctor-patient communication. 1. Doctor-patient interaction and patient satisfaction. Pediatrics. 1968;42:855-871.
15. Roter D, Hall JA. Doctor-patient communication: Why and how communication contributes to the quality of medical care. In: Gellman MD, Turner JR, eds. Encyclopedia of Behavioral Medicine. New York: Springer, 2013, 622-627.
16. Levinson W, Lesser CS, Epstein RM. Developing physician communication skills for patient-centered care. Health Aff (Millwood). 2010;29:1310-1318.
17. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement JAMA. 1999;282:1458-1465.
18. Cushman WC, Basile J. Achieving blood pressure goals: why aren't we? J Clin Hypertens (Greenwich). 2006;8:865-872.
19. Balu S. Estimated annual direct expenditures in the United States as a result of inappropriate hypertension treatment according to national treatment guidelines. Clin Ther. 2009;31:1581-1594.
20. Michie S, Johnston M. Changing clinical behaviour by making guidelines specific. BMJ. 2004;328:343-345.
21. Rümenapf G. Incomprehensible jargon. Dtsch Arztebl Int. 2011;108:492.
22. Redon J, Erdine S, Böhm M, et al; On behalf of the SHARE Steering Committee. Physician attitudes to blood pressure control: findings from the Supporting Hypertension Awareness and Research Europe-wide survey. J Hypertens. 2011;29:1633-1640.
23. Luders S, Schrader J, Schmieder RE, et al. Improvement of hypertension management by structured physician education and feedback system: cluster randomized trial. Eur J Cardiovasc Prev Rehabil. 2009;17:271-279.
24. Hill MN, Miller NH, de Geest S; On behalf of the American Society of Hypertension Writing Group. ASH Position Paper: adherence and persistence with taking medication to control high blood pressure. J Clin Hypertens (Greenwich). 2010;12:757-764.
25. Voogdt-Pruis HR, van Ree JW, Gorgels AP, Beusmans GH. Adherence to a guideline on cardiovascular prevention: a comparison between general practitioners and practice nurses. Int J Nurs Stud. 2011;48:798-807.
26. Valderrama AL, Tong X, Ayala C, Keenan NL. Prevalence of self-reported hypertension, advice received from health care professionals, and actions taken to reduce blood pressure among US adults-HealthStyles, 2008. J Clin Hypertens (Greenwich). 2010;12:784-792.
27. http://www.heartresearch.com.au/assets/files/Take_Heart_Newsletters/200810.pdf. Accessed January 28, 2013.
28. Turner JR, Strumph P. The moral imperative of improving patient adherence to pharmacotherapy for cardiodiabesity, Part I: a focus on type 2 diabetes mellitus. J Patient Compliance. 2012;2(1):32-36.
29. Richards AL, Turner JR. The moral imperative of improving patient adherence to pharmacotherapy for cardiodiabesity, Part II: a focus on cardiovascular disease. J Patient Compliance. 2012;2(2):36-41.
30. Society for Behavioral Medicine. http://www.sbm.org/. Accessed February 26, 2013.
31. Society for Behavioral Medicine. http://www.sbm.org/publications. Accessed February 26, 2013.
32. Script Your Future Initiative. http://www.scriptyourfuture.org/wp-content/themes/cons/m/SYF_PressRelease_FINAL.pdf. Accessed February 26, 2013.
33. FDA. http://www.fda.gov/Drugs/DrugSafety/SafeUseInitiative/ucm188762.htm. Accessed February 26, 2013.
34. American Medical Association. http://www.ama-assn.org/. Accessed February 28, 2013.
35. American Association of Colleges of Pharmacy. http://www.aacp.org/. Accessed February 28, 2013.
36. Medication Adherence Team Challenge. http://syfadherencechallenge.ning.com. Accessed February 26, 2013.
37. Armario P, Waeber B. Therapeutic strategies to improve control of hypertension. J Hypertens. 2013;31(Suppl 1):S9-S12.
38. Huan Y, Townsend R. The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide in the treatment of hypertension. Expert Opin Pharmacother. 2012;13:2409-2415.
39. Kumagai N, Onishi K, Hoshino K, et al. Improving drug adherence using fixed combinations caused beneficial treatment outcomes and decreased health-care costs in patients with hypertension. Clin Exp Hypertens. 2012. Oct 16. [Epub ahead of print].
40. Panjabi S, Lacey M, Bancroft T, Cao F. Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients. J Am Soc Hypertens. 2013;7:46-60.
41. Tocci G, Paneni F, Passerini J, Volpe M. Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy. Expert Opin Pharmacother. 2012;13:2687-2697.
42. Volpe M, Tocci G. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. Vasc Health Risk Manag. 2012;8:371-380.
43. Dolan E, O'Brien E. Blood pressure variability: clarity for clinical practice. Hypertension. 2010;56:179-181.
44. Gindlesberger DR. Office-based nursing staff management of hypertension in primary care. WMJ. 2012;111:183-184.
45. Hegney DG, Patterson E, Eley DS, et al. The feasibility, acceptability and sustainability of nurse-led chronic disease management in Australian general practice: the perspectives of key stakeholders. Int J Nurs Pract. 2013;19:54-59.
46. Allen JK, Dennison-Himmelfarb CR, Szanton SL, et al. Community Outreach and Cardiovascular Health (COACH) Trial: a randomized, controlled trial of nurse practitioner/community health worker cardiovascular disease risk reduction in urban community health centers. Circ Cardiovasc Qual Outcomes. 2011;4:595-602.
47. Johnson W, Shaya FT, Khanna N, et al. The Baltimore Partnership to Educate and Achieve Control of Hypertension (The BPTEACH Trial): a randomized trial of the effect of education on improving blood pressure control in a largely African American population. J Clin Hypertens (Greenwich). 2011;13:563-570.
48. Moran B, Walsh T. Cardiovascular disease in women: how nurses can promote awareness and prevention. Nurs Womens Health. 2013;17:63-68.
49. Chang AK, Fritschi C, Kim MJ. Nurse-led empowerment strategies for hypertensive patients with metabolic syndrome. Contemp Nurse. 2012;42:118-128.
50. Drevenhorn E, Bengtson A, Nilsson PM, et al. Consultation training of nurses for cardiovascular prevention - a randomized study of 2 years duration. Blood Press. 2012;21:293-299.
51. Chua SS, Kok LC, Yusof FA, et al. Pharmaceutical care issues identified by pharmacists in patients with diabetes, hypertension or hyperlipidaemia in primary care settings. BMC Health Serv Res. 2012;12:388.
52. Kirschner K, Braspenning J, Jacobs JE, Grol R. Design choices made by target users for a pay-for-performance program in primary care: an action research approach. BMC Fam Pract. 2012;13:25.
53. Lee TH, Ferris TG. Pay for performance: a work in progress. Circulation. 2009;119:2965-2966.
54. McDonald R, Roland M. Pay for performance in primary care in England and California: comparison of unintended consequences. Ann Fam Med. 2009;7:121-127.
55. Petersen LA, Urech T, Simpson K, et al. Design, rationale, and baseline characteristics of a cluster randomized controlled trial of pay for performance for hypertension treatment: study protocol. Implement Sci. 2011;6:114.
56. Petersen LA, Woodard LD, Henderson LM, et al. Will hypertension performance measures used for pay-for-performance programs penalize those who care for medically complex patients? Circulation. 2009;119:2978-2985.
57. Serumaga B, Ross-Degnan D, Avery AJ, et al. Effect of pay for performance on the management and outcomes of hypertension in the United Kingdom: interrupted time series study. BMJ. 2011;342:d108.
58. Scott A, Sivey P, Ait OD, et al. The effect of financial incentives on the quality of health care provided by primary care physicians. Cochrane Database Syst Rev. 2011;9:CD008451.
59. Ryan AM, Doran T. The effect of improving processes of care on patient outcomes: evidence from the United Kingdom's quality and outcomes framework. Med Care. 2012;50:191-199.
60. Koenigsfeld CF, Horning KK, Logemann CD, Schmidt GA. Medication therapy management in the primary care setting: a pharmacist-based pay-for-performance project. J Pharm Pract. 2012;25:89-95.
61. Long JA, Helweg-Larsen M, Volpp KG. Patient opinions regarding 'pay for performance for patients'. J Gen Intern Med. 2008;23:1647-1652.
62. Wu J. Rewarding healthy behaviors-pay patients for performance. Ann Fam Med. 2012;10:261-263.
63. Chernew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Aff (Millwood). 2007;26:w195-w203.
64. Farley JF, Wansink D, Lindquist JH, et al. Medication adherence changes following value-based insurance design. Am J Manag Care. 2012;18:265-274.
65. Frank MB, Fendrick AM, He Y, et al. The effect of a large regional health plan's value-based insurance design program on statin use. Med Care. 2012;50:934-939.
66. Kim YA, Loucks A, Yokoyama G, et al. Evaluation of value-based insurance design with a large retail employer. Am J Manag Care. 2011;17:682-690.
67. Chernew ME, Juster IA, Shah M, et al. Evidence that value-based insurance can be effective. Health Aff (Millwood). 2010;29:530-536.
68. Choudhry NK, Avorn J, Glynn RJ, et al; Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:2088-2097.
69. Choudhry NK, Fischer MA, Avorn JL, et al. The impact of reducing cardiovascular medication copayments on health spending and resource utilization. J Am Coll Cardiol. 2012;60:1817-1824.
70. Volpp KG, Loewenstein G, Asch DA. Assessing value in health care programs. JAMA. 2012;307:2153-2154.